Biogen’s Tony Kingsley has moved to The Medicines Company to take up the role of chief operating officer, where he will help oversee the New Jersey firm’s day-to-day operations and lead its commercial activities.
He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who retired in January.
Clive Meanwell, chief executive officer of The Medicines Company, said: “Tony brings extensive leadership experience and broad operational expertise developed over a long and enormously successful career.
“His contributions will be invaluable as the company enters this exciting period and we continue to execute on our strategy to drive growth from our core, high-value assets, while maximising strategic and operational flexibility.”
Kingsley previously served as Biogen’s executive vice president, global commercial operations, where the product launches he oversaw included the multiple sclerosis blockbuster Tecfidera (dimethyl fumerate).
Prior to that he spent time at Hologic as general manager of its gynaecological surgical products business and at Cytyc Corporation as president of its diagnostic products division.
Kingsley also previously worked as a partner at McKinsey & Company focusing on the biotechnology, pharmaceutical and medical device industries.
He said: “This is an extraordinary opportunity to be part of a company that carries the promise of profoundly improving and extending the lives of so many, while fundamentally altering the competitive landscape.”